Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial

被引：0
|
作者：
Beck, Lisa A. [1 ]
Deleuran, Mette [2 ]
Hong, H. Chih-Ho [3 ,4 ]
Adam, David N. [4 ,5 ,6 ]
Hussain, Iftikhar [7 ]
Zhang, Haixin [8 ]
Shabbir, Arsalan [8 ]
Rodriguez Marco, Ainara [9 ]
Levit, Noah A. [8 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Univ British Columbia, Surrey, BC, Canada
[4] Canada Prob Med Res, Waterloo, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] CCA Med Res, Ajax, ON, Canada
[7] Vital Prospects Clin Res Inst PC, Tulsa, OK USA
[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[9] Sanofi Genzyme, Madrid, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
34385
引用
收藏
页码：AB206 / AB206
页数：1
相关论文
共 50 条
  • [21] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: open-label extension study
    Blauvelt, A.
    Wollenberg, A.
    Beck, L. A.
    Chen, Z.
    Vakil, J.
    Khokhar, F. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E120 - E121
  • [22] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
    Cork, M. J.
    Thaci, D.
    Eichenfield, L. F.
    Arkwright, P. D.
    Hultsch, T.
    Davis, J. D.
    Zhang, Y.
    Zhu, X.
    Chen, Z.
    Li, M.
    Ardeleanu, M.
    Teper, A.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Ruddy, M.
    Graham, N. M. H.
    Pirozzi, G.
    Stahl, N.
    DiCioccio, A. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
  • [23] Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial
    Zhao, Yan
    Li, Jing-Yi
    Yang, Bin
    Ding, Yang-Feng
    Wu, Li-Ming
    Zhang, Li-Tao
    Wang, Jin-Yan
    Lu, Qian-Jin
    Zhang, Chun-Lei
    Zhang, Fu-Ren
    Zhu, Xiao-Hong
    Li, Yu-Mei
    Tao, Xiao-Hua
    Diao, Qing-Chun
    Li, Lin-Feng
    Lu, Jian-Yun
    Man, Xiao-Yong
    Li, Fu-Qiu
    Xia, Xiu-Juan
    Song, Jiao-Ran
    Jia, Ying-Min
    Zhang, Li-Bo
    Chen, Bo
    Zhang, Jian-Zhong
    BIODRUGS, 2024, 38 (05) : 681 - 689
  • [24] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Open-Label Extension (OLE) study
    Blauvelt, A.
    Wollenberg, A.
    Chen, Z.
    Bastian, M.
    Zhang, M.
    Khokhar, F. A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 66
  • [25] Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
    Wechsler, Michael E.
    Ford, Linda B.
    Maspero, Jorge F.
    Pavord, Ian D.
    Papi, Alberto
    Bourdin, Arnaud
    Watz, Henrik
    Castro, Mario
    Nenasheva, Natalia M.
    Tohda, Yuji
    Langton, David
    Cardona, Guido
    Domingo, Christian
    Park, Hae Sim
    Chapman, Kenneth R.
    Mao, Xuezhou
    Zhang, Yi
    Khan, Asif H.
    Deniz, Yamo
    Rowe, Paul J.
    Kapoor, Upender
    Khokhar, Faisal A.
    Mannent, Leda P.
    Ruddy, Marcella
    Laws, Elizabeth
    Amin, Nikhil
    Hardin, Megan
    LANCET RESPIRATORY MEDICINE, 2022, 10 (01): : 11 - 25
  • [26] EFFICACY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Gonzalez, T.
    Xiao, J.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S90 - S91
  • [27] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [28] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [29] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [30] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
12345